Review Update on Pneumococcal Conjugate Vaccine: A New Hope for Reduction of Pneumococcal Disease in Bangladesh

  • Jannatul Fardows Assistant Professor, Department of Microbiology, International Medical College, Gazipur
  • Abu Bakar Siddique Assistant Register, Department of Medicine, Dhaka Medical College, Dhaka
  • Nasren Farhana Lecturer, Department of Microbiology, Dhaka Medical College, Dhaka
  • Tasmine Binte Islam Assistant Professor, Department of Microbiology, Tairunnessa Memorial Medical College, Gazipur
Keywords: Pneumococcal disease, PCV10, PCV13, world health organization, EPI

Abstract

Pneumococcal diseases are the common and widely distributed disease in the world. It causes various mortality and morbidity every year, mainly in the developing countries. Pneumococcal conjugate vaccine (PCV) is the new vaccine against all invasive pneumococcal diseases. PCV10 and PCV13 are the available preparation in worldwide. It is safe, highly antigenic and minimal side effects. In Bangladesh, PCV is included in EPI schedule from April 2015. The current preparation is Synforix PCV10, which is given intramuscularly with the pentavalent vaccine in EPI schedule. In conclusion, the assessment of PCV impact in Bangladesh requires national and regional level surveillance and the introduction of PCV in EPI will reduce the mortality and morbidity of the pneumococcal disease.

Bangladesh J Infect Dis 2015;2(1):19-22

Downloads

Download data is not yet available.
Abstract
2265
PDF
685
Published
2017-01-30
How to Cite
Fardows, J., Siddique, A., Farhana, N., & Islam, T. (2017). Review Update on Pneumococcal Conjugate Vaccine: A New Hope for Reduction of Pneumococcal Disease in Bangladesh. Bangladesh Journal of Infectious Diseases, 2(1), 19-22. https://doi.org/10.3329/bjid.v2i1.31325
Section
Review Articles